Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09PVO
|
|||
| Former ID |
DIB007998
|
|||
| Drug Name |
Aramchol
|
|||
| Synonyms |
Stearoyl CoA desaturase-1 inhibitor (oral, liver/lipid metabolism diseases), Galmed
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Lipid metabolism disorder [ICD-11: 5C52.Z] | Phase 2/3 | [1] | |
| Company |
Galmed Medical Research Ltd
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C44H79NO5
|
|||
| Canonical SMILES |
CCCCCCCCCCCCCCCCCCCC(=O)NC1CCC2(C(C1)CC(C3C2CC(C4(C3CCC4C(C)CCC(=O)O)C)O)O)C
|
|||
| InChI |
1S/C44H79NO5/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-40(48)45-34-27-28-43(3)33(29-34)30-38(46)42-36-25-24-35(32(2)23-26-41(49)50)44(36,4)39(47)31-37(42)43/h32-39,42,46-47H,5-31H2,1-4H3,(H,45,48)(H,49,50)/t32-,33+,34+,35-,36+,37+,38-,39+,42+,43+,44-/m1/s1
|
|||
| InChIKey |
SHKXZIQNFMOPBS-OOMQYRRCSA-N
|
|||
| CAS Number |
CAS 246529-22-6
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Acyl-CoA desaturase (SCD) | Target Info | Inhibitor | [2], [3] |
| KEGG Pathway | Metabolic pathways | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02279524) A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH. U.S. National Institutes of Health. | |||
| REF 2 | The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014 Dec;12(12):2085-91.e1. | |||
| REF 3 | Fatty acid bile acid conjugate inhibits hepatic stearoyl coenzyme A desaturase and is non-atherogenic. Arch Med Res. 2010 Aug;41(6):397-404. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.